CLINICAL PRACTICE GUIDELINES
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship

Investor Relations

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

Market Performance

4C Q2 FY'24

Quarterly Results Conference Call

4C Q1 FY'24

Quarterly Results Investor Presentation

MAY 2023

Complete Investor Presentation

Analyst coverage

ImpediMed has market-leading coverage with the following entities:

Share register

ImpediMed Limited is listed on the Australian Stock Exchange (ASX). Trading in its securities is under the ticker code on ASX of “IPD” for ordinary shares.


Share register agent

To update shareholder contact information or submit transfer documents, please contact ImpediMed’s share register service provider:

linkmarketservices.com.au

Ph: +1300-554-474
Fax: +61-2-9287-0303

Locked Bag A14
Sydney South
NSW 1235, Australia


Shareholder services

Shares may be bought on market through any Australian stock broker, or through on-market trades, via a number of international brokerage houses. If you are a potential investor needing information on how to trade in shares through an international brokerage house, please contact:

InvestorRelations@impedimed.com

ImpediMed maintains an active communications program with investors and the market.


My shareholding

ImpediMed’s share register is managed by Link Market Services Limited.

ImpediMed is focused on reducing our carbon footprint whilst providing you with timely corporate updates and disclosures.

Recent legislative changes to the Corporations Act 2001 (Cth) mean there are new options for how ImpediMed shareholders receive communications. ImpediMed will no longer send physical meeting documents unless a shareholder requests a copy to be mailed.

Electronic communication has the added advantage of being timelier and more cost effective, which benefits all shareholders, and ImpediMed encourages all shareholders to provide an email address so we can communicate with you electronically when shareholder notices become available online, for items such as meeting documents, dividend statements and annual reports.

Shareholders can still elect to receive some or all of their communications in physical or electronic form. To review your communication preference, or sign up to receive your shareholder communications via email, please update your details at the Link Investor Centre https://investorcentre.linkmarketservices.com.au/Login/Login.

If you are a Shareholder and require an additional copy of a communication, need further information about the options available to you or have questions about your holding, visit the Link Investor Centre https://www.linkmarketservices.com.au/ or contact the Registry:

Link Market Services
Locked Bag A14
Sydney South NSW 1235
P: +61 1300 554 474 (toll free within Australia)
registrars@linkmarketservices.com.au
www.linkmarketservices.com.au

Shareholders can use the Link Investor Centre at https://investorcentre.linkmarketservices.com.au/Login/Login to:

Set up and add their holdings to a portfolio
Review and update their contact details, communication preferences and payment
instructions
Provide their TFN and/or ABN
View their holding details
Make online enquiries

To view your shareholding Link Investor Centre, visit: https://investorcentre.linkmarketservices.com.au/Login/Login.


Investor Relations Contact

Hannah Howlett
WE Communications
+61 (0) 4 5064 8064
hhowlett@we-worldwide.com
InvestorRelations@impedimed.com